Evidence map›Paper›PMID 42041597›Full record

ArticleCells2026

Single-Cell Transcriptomics Reveals Immune Modulation by Telmisartan in Colorectal Cancer.

Jinxin Li, Decao Yang, Xiaoyue Wang, Runqing Ju, Shaomeng Chen, Jingyi Zhao, Jiaxing Xu, Jiaxin Chen, Jiayu Ye, Baohui Xu and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cells, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Jinxin LiInstitute of Medical Innovation and Research, Peking University Third Hospital, Beijing 100191, China.ORCID 0009-0005-5786-5122
Decao YangInstitute of Medical Innovation and Research, Peking University Third Hospital, Beijing 100191, China.
Xiaoyue WangInstitute of Medical Innovation and Research, Peking University Third Hospital, Beijing 100191, China.
Runqing JuInstitute of Medical Innovation and Research, Peking University Third Hospital, Beijing 100191, China.
Shaomeng ChenInstitute of Medical Innovation and Research, Peking University Third Hospital, Beijing 100191, China.
Jingyi ZhaoInstitute of Medical Innovation and Research, Peking University Third Hospital, Beijing 100191, China.
Jiaxing XuInstitute of Medical Innovation and Research, Peking University Third Hospital, Beijing 100191, China.
Jiaxin ChenInstitute of Medical Innovation and Research, Peking University Third Hospital, Beijing 100191, China.
Jiayu YeDepartment of Medicine, School of Medicine, Stanford University, Stanford, CA 94305, USA.ORCID 0000-0002-1704-6780
Baohui XuDivision of Vascular Surgery, Department of Surgery, School of Medicine, Stanford University, Stanford, 94305 CA, USA.ORCID 0000-0002-2857-7464
Qianqian YinInstitute of Medical Innovation and Research, Peking University Third Hospital, Beijing 100191, China.
Yan WangInstitute of Medical Innovation and Research, Peking University Third Hospital, Beijing 100191, China.

Funding

National Natural Science Foundation of China 82001248National Natural Science Foundation of China 82471329
6 · The paper itself

Abstract

Telmisartan, an angiotensin II type 1 receptor blocker with established anti-inflammatory and antihypertensive properties, has been reported to inhibit tumor cell proliferation, yet its impact on the tumor immune microenvironment remains poorly understood. In this study, we evaluated the immunomodulatory effects of telmisartan using a syngeneic MC38 colorectal cancer model in C57BL/6 mice. Daily intragastric administration of telmisartan significantly suppressed tumor growth and reduced endpoint tumor weight compared with controls. To elucidate the underlying mechanisms, we performed single-cell RNA sequencing on tumor-infiltrating CD45

Indexed as

Colorectal NeoplasmsImmunomodulationSingle-Cell AnalysisTelmisartanTranscriptomeAnimalsCell Line, TumorGene Expression Regulation, NeoplasticMacrophagesMiceMice, Inbred C57BLT-Lymphocytes, RegulatoryTumor MicroenvironmentTelmisartancolorectal cancermacrophageT celltelmisartantumor microenvironment

Identifiers

PMID42041597
PMCPMC13114542

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.